drugset / Trial / NCT05004675
Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Comparison of LDL-C reductions of lerodalcibep (LIB003) 300 mg to inclisiran (Leqvio®) 284 in patients at very-high risk or high-risk for CVD on stable diet and oral LDL-C-lowering drug therapy
Timeline
- Start
- 2022-06-20
- Primary completion
- 2024-05-30
- Completion
- 2024-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Inclisiran | Small interfering RNA (siRNA) | 284 mg | Subcutaneous |
| Subject | lerodalcibep | Protein / enzyme biologic | 300 mg | Subcutaneous |